Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2023 | Discriminative power of a multi-PET tracer approach in primary tauopathies

Mona-Lisa Malarte, PhD Candidate, Center of Alzheimer Research, Karolinska Institutet, Stockholm, Sweden, shares her work using a multi-PET tracer approach to investigate astrocytic and tau pathologies in 4R tauopathies, hoping to gain new mechanistic insights and identify potential discriminatory features. Corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) show common features than can make a differential clinical diagnosis challenging. There is a need for new methods that enables early, differential diagnosis in this setting. Therefore, Ms Malarte is working to characterize different PET tracers in CBD and PSP to gain a deeper understanding of tau spatial distribution and its relationship with astrocyte reactivity. Preliminary data from post-mortem samples indicate that astrocytic tracers show different binding intensities in different brain regions, comparable with tau PET tracer 3H-PI2620 binding. Additionally, these astrocytic tracers showed two binding sites in the putamen of CBD cases, but only one site in PSP. Ongoing multi-PET tracer studies will provide new insights on the individual pathological profiles of PSP and CBD. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2023 in Amsterdam, Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.